ClinicalTrials.Veeva

Menu
U

University of Tennessee Medical Center | Office of Clinical Trials

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gemcitabine
Pembrolizumab
Docetaxel
Cemiplimab
VX-121
Paclitaxel
Abemaciclib
Fianlimab
GC4419
LY2835219

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

46 of 133 total trials

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer...

Enrolling
Alzheimer Disease 6
Cognitive Impairment
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active
Locations recently updated

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for athero...

Enrolling
Diabetes Mellitus, Type 2
Metabolic Syndrome
Device: The Cleerly CAD Staging System

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with r...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Cyclophosphamide

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in pa...

Active, not recruiting
Cystic Fibrosis
Drug: VX-121/TEZ/D-IVA

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Tislelizumab

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

This is a multi-center, open-label trial to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavuserti...

Enrolling
Refractory Hematologic Malignancy
Refractory Primary Central Nervous System Lymphoma
Drug: ibrutinib
Drug: Emavusertib

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.The aim is to find...

Enrolling
Non-Small Cell Lung Cancer
Drug: Cemiplimab
Drug: REGN7075

This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with...

Active, not recruiting
Biliary Tract Cancer
Gall Bladder Cancer
Drug: CTX-009
Drug: Paclitaxel

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women wit...

Active, not recruiting
Breast Cancer
Drug: Abemaciclib
Drug: Anastrozole

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: Cisplatin
Radiation: Hypo-fractioned radiation therapy

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or...

Active, not recruiting
Chronic Lymphocytic Leukemia (CLL)
Drug: Bendamustine
Drug: Rituximab

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling
Non-Muscle Invasive Bladder Cancer
Drug: Gemcitabine
Drug: MMC

A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV pa...

Enrolling
Light Chain (AL) Amyloidosis
Drug: Birtamimab
Other: Placebo

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REG...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: cemiplimab
Drug: Placebo

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also kn...

Enrolling
Melanoma
Drug: fianlimab
Drug: cemiplimab

Trial sponsors

Regeneron Pharmaceuticals logo
Lilly logo
University of Tennessee logo
U
Pfizer logo
Vertex Pharmaceuticals logo
NewLink Genetics logo
U
Amgen logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems